RxDoctor Payments Data

Jiji George, NP

Psychiatric/Mental Health · New Hyde Park, NYNPI 1548516867

Payments from drug & device makers

$3,082in general payments, 2019–2025

Across 79 payments — averaging $39.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$932
  • AbbVie$868
  • Axsome Therapeutics, Inc.$425
  • E.r. Squibb & Sons, L.L.C.$154
  • Alkermes, Inc.$120
  • Neurocrine Biosciences, Inc.$114
  • plus $469 from 8 others

What the payments were for

  • Food & beverage$2,95996%
  • Education$1234%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,082 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$32,334
Medicare patients
49
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide12$17,358
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$1,303
Quetiapine Fumarate57$1,260
Aripiprazole44$1,131
Venlafaxine Hcl ErVenlafaxine Hcl66$970
Duloxetine Hcl81$934
Alprazolam140$856
Bupropion XlBupropion Hcl41$828
Escitalopram Oxalate99$658
Sertraline Hcl48$360
Mirtazapine26$333
Lamotrigine41$323
Risperidone37$321
Gabapentin29$292
Fluoxetine Hcl34$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$38$17,35812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →